Ending Self-Stigma Program for HIV/AIDS with Substance Use
(IRIS Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to determine if the Ending Self-Stigma Program for Persons Living with HIV and Substance Use can reduce stigma among individuals with HIV who also use opioids or cocaine. Researchers seek to understand whether improved self-perception enhances HIV care and treatment outcomes. Participants will either continue their usual care or participate in five online sessions with a trained counselor to address negative self-thoughts and boost confidence in managing HIV and substance use. This trial suits English-speaking individuals living with HIV who have used drugs or are in substance use treatment and have experienced stigma related to their HIV status or substance use. As an unphased trial, it offers a unique opportunity to contribute to understanding and improving self-stigma interventions for those living with HIV and substance use.
Do I need to stop my current medications to join the trial?
The trial information does not specify whether you need to stop taking your current medications. It focuses on reducing stigma among people with HIV who use opioids and cocaine.
What prior data suggests that this intervention is safe for people living with HIV who use substances?
Research shows that programs designed to reduce self-stigma are generally safe for people. These programs can help individuals with mental health issues combat negative self-perceptions. The program in this trial builds on this concept and uses cognitive behavioral therapy, a type of talk therapy that helps people change negative thinking patterns.
A review of similar programs found that participants generally handle them well, with no major reports of harm or negative effects. This suggests that the treatment is safe for people in the trial. Although the program is newly adapted for individuals with HIV and substance use issues, it is based on proven methods. This background provides some confidence in its safety for participants.12345Why are researchers excited about this trial?
Researchers are excited about the Ending Self-Stigma Program for HIV/AIDS with Substance Use because it targets internalized stigma, a factor often overlooked in traditional treatments. Unlike standard care options, which primarily focus on medical management and counseling, this program uses cognitive behavioral therapy and social cognitive theory to tackle negative self-perceptions. The treatment is delivered through virtual sessions, making it accessible and convenient for participants who may face barriers to in-person therapy. By improving self-efficacy and reducing self-stigma, this program has the potential to enhance engagement with existing HIV and substance use treatments, offering a holistic approach to care.
What evidence suggests that the Ending Self-Stigma Program is effective for reducing stigma in people living with HIV who use substances?
Research shows that programs aimed at reducing self-stigma can improve mental health and care engagement for people living with HIV who also use substances. In this trial, participants may receive the Ending Self-Stigma Program, which uses methods like cognitive behavioral therapy to change negative self-views and boost confidence effectively. Evidence suggests that addressing stigma can lead to better health by helping people adhere to their treatment plans. Early results from similar programs demonstrated positive effects in reducing shame and improving overall well-being. These findings suggest that the Ending Self-Stigma Program may enhance HIV care by addressing internalized stigma.36789
Who Is on the Research Team?
Jesse B Fletcher, Ph.D.
Principal Investigator
Friends Research Institute, Inc.
Alicia Lucksted, Ph.D.
Principal Investigator
University of Maryland
Are You a Good Fit for This Trial?
This trial is for adults over 18 living with HIV who also use opioids or cocaine. Participants must have experienced stigma related to their HIV status or substance use, be able to give informed consent, and speak English.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Intervention Adaptation
Adaptation of the existing intervention to be applied specifically among people living with HIV who use substances, including formative interviews and pilot studies.
Treatment
Participants receive either the newly adapted ESS-HSU intervention or minimally enhanced treatment-as-usual. The ESS-HSU intervention consists of up to nine group-based virtual sessions.
Follow-up
Participants are monitored for primary HIV-related outcomes including ART adherence, viral suppression, and retention in HIV healthcare.
What Are the Treatments Tested in This Trial?
Interventions
- Ending Self Stigma for Persons living with HIV and Use Substances
Find a Clinic Near You
Who Is Running the Clinical Trial?
Friends Research Institute, Inc.
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator
University of Maryland
Collaborator
National Institute on Drug Abuse (NIDA)
Collaborator
Johns Hopkins University
Collaborator